Bayer sold HIV-contaminated blood products to hemophiliacs in Asia and Latin America after pulling them from US market

When hemophiliacs began dying from AIDS in the 1980s, the cause wasn't immediately obvious. These patients, who relied on blood-clotting products to survive their genetic condition, were contracting HIV at alarming rates. What came to light years later would reveal a deliberate choice by one of the world's largest pharmaceutical companies to prioritize profit over lives.

Bayer's Cutter Biological division manufactured Factor VIII, a blood concentrate essential for hemophiliacs. When HIV contamination in blood products became known, the company faced a choice: destroy existing inventory or find another market. They chose the latter. Internal documents later showed Cutter continued selling the older, HIV-contaminated version of Factor VIII in Asia and Latin America, even after introducing a heat-treated, safer version domestically in the United States.

The company's decision was coldly financial. Rather than absorb the cost of destroying contaminated stock, Bayer executives determined it was more economical to sell the risky product overseas. The products carried the same risk of HIV transmission, yet were marketed to populations with less regulatory oversight and less ability to pursue legal recourse. The company essentially decided that lives in developing nations were worth less than the cost of proper disposal.

When these claims emerged, pharmaceutical industry defenders argued there was insufficient evidence linking the contaminated products to HIV infection and that companies were acting within the regulatory framework of the time. The official position suggested that disposing of safe blood products would have been wasteful, and that other factors may have contributed to infections. Some argued that heat-treating all blood products wasn't universally standard practice immediately upon discovery of HIV contamination.

The New York Times investigation in 2003 changed that narrative. The newspaper obtained internal Bayer documents showing executives explicitly knew about the contamination risk and the availability of the safer alternative. The company's own records revealed conversations about selling the existing stock to avoid financial loss. These weren't speculative claims or circumstantial inferences—they were the company's own words documenting the decision.